The most commonly reported side effects of technetium tc-99m tilmanocept include off label use, injection site pain, and rash, based on 184 FDA adverse event reports from 2014 to 2025. 66.8% of reports found the drug to be ineffective.
Percentages show how often each reaction appears relative to total reports for technetium tc-99m tilmanocept.
These are voluntary reports and do not establish that technetium tc-99m tilmanocept caused these reactions.
Report severity
Seriousness is determined by the reporter, not by OpenClaim.
Other drugs that appear in adverse event reports alongside technetium tc-99m tilmanocept. Drugs flagged as a suspected cause appear in the first column. Drugs taken at the same time but not suspected appear in the second.
Also suspected
Taken alongside
Co-occurrence in adverse event reports does not establish a drug interaction. Patients often take multiple medications, and these lists reflect prescribing patterns rather than causal relationships. Consult a healthcare provider about potential drug interactions.
73.4% of technetium tc-99m tilmanocept adverse event reports involve female patients and 9.8% involve male patients. The largest age group is elderly at 57%. These figures reflect who reports side effects, not underlying risk.
Sex
Age group
Conditions and purposes for which patients were taking technetium tc-99m tilmanocept when the adverse event was reported.
Technetium Tc-99m Tilmanocept is sold under the brand name Lymphoseek Kit.
An upward trend reflects increased FAERS reporting overall, not necessarily increased risk.
Ask OpenClaim about your specific drug combination. Get a sourced report using FDA data, drug labels, and medical literature.